1. Bevacizumab Combined with S‐1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study. (30th April 2021) Authors: Chen, Ye; Zhou, Yu‐Wen; Cheng, Ke; Li, Zhi‐Ping; Luo, De‐Yun; Qiu, Meng; Li, Qiu; Wang, Xin; Shen, Ya‐Li; Cao, Dan; Yang, Yu; Bi, Feng; Liu, Ji‐Yan; Gou, Hong‐Feng Journal: Oncologist Issue: Volume 26:Number 8(2021) Page Start: e1320 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Enhancement of the antitumor effect of HER2‐directed CAR‐T cells through blocking epithelial‐mesenchymal transition in tumor cells. Issue 8 (9th July 2020) Authors: Zhang, Peng‐Fei; Huang, Yong; Liang, Xiao; Li, Dan; Jiang, Lin; Yang, Xiao; Zhu, Min; Gou, Hong‐Feng; Gong, You‐Ling; Wei, Yu‐Quan; Li, Qiu; Wang, Wei Journal: FASEB journal Issue: Volume 34:Issue 8(2020) Page Start: 11185 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component. (3rd May 2021) Authors: Zhou, Yu‐Wen; Long, Yi‐Xiu; Chen, Ye; Liu, Ji‐Yan; Pu, Dan; Huang, Jia‐Yan; Bi, Feng; Li, Qiu; Gou, Hong‐Feng; Qiu, Meng Journal: Cancer medicine Issue: Volume 10:Number 10(2021) Page Start: 3388 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. IL‐18R‐dependent and independent pathways account for IL‐18‐enhanced antitumor ability of CAR‐T cells. Issue 1 (6th December 2019) Authors: Huang, Yong; Li, Dan; Zhang, Peng‐Fei; Liu, Mei; Liang, Xiao; Yang, Xiao; Jiang, Lin; Zhang, Li‐Feng; Zhou, Wei‐Lin; Su, Jin‐Hua; Gong, You‐Ling; Gou, Hong‐Feng; Wei, Yu‐Quan; Wang, Wei Journal: FASEB journal Issue: Volume 34:Issue 1(2020) Page Start: 1768 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. S‐1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial. (16th January 2019) Authors: Chen, Ye; Wu, Jing; Cheng, Ke; Li, Zhi‐Ping; Luo, De‐Yun; Qiu, Meng; Gou, Hong‐Feng; Yi, Cheng; Li, Qiu; Wang, Xin; Yang, Yu; Cao, Dan; Shen, Ya‐Li; Bi, Feng; Liu, Ji‐Yan Journal: Oncologist Issue: Volume 24:Number 5(2019) Page Start: 591 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗